Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)

Summit Therapeutics (SMMT) has reported Non-Current Debt for 3 consecutive years, with $100.0 million the latest figure, recorded in Q1 2024.

• Quarterly Non-Current Debt changed 0.0% year-over-year to $100.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $100.0 million (changed 0.0% YoY) and the FY2023 annual result came in at $100.0 million, down 79.78% from the prior year.
• Non-Current Debt steadied at $100.0 million in Q1 2024 per SMMT's latest filing, from $100.0 million in the prior quarter.
• Over the last five years, Non-Current Debt for SMMT reached as high as $494.5 million in Q4 2022 and fell as low as $25.1 million in Q1 2022.
• A 3-year average of $135.0 million and a median of $100.0 million in 2023 frame the typical range for Non-Current Debt.
• The largest YoY upside for Non-Current Debt was 299.12% in 2023 against a maximum downside of 79.78% in 2023.
• Year by year, Non-Current Debt stood at $494.5 million in 2022, then plunged by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
• According to Business Quant data, Non-Current Debt over the past three periods registered $100.0 million, $100.0 million, and $100.0 million for Q1 2024, Q4 2023, and Q2 2023 respectively.